<DOC>
	<DOCNO>NCT01367002</DOCNO>
	<brief_summary>The primary objective study estimate whether addition trastuzumab paclitaxel carboplatin chemotherapy improve progression free survival compare paclitaxel carboplatin alone Uterine Serous Papillary Carcinoma ( USPC ) patient overexpressing Her2/neu 3+ level immunohistochemistry ( IHC ) positive fluorescence situ hybridization ( FISH ) .</brief_summary>
	<brief_title>Evaluation Carboplatin/Paclitaxel With Without Trastuzumab ( Herceptin ) Uterine Serous Cancer</brief_title>
	<detailed_description>The purpose study perform randomize Phase II evaluation Carboplatin/Paclitaxel without Trastuzumab ( Herceptin ) patient HER2/neu+ advance stage/recurrent disease emphasis determine progression free survival USPC patient assess immunologic marker predictive trastuzumab response .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Papillary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must advance ( stage IIIIV ) recurrent histologically confirm USPC measurable disease . Patients must harbor tumor HER2/neu+ base upon IHC stain score 3+ 2+ confirm gene amplification FISH Patients history invasive malignancy , exception nonmelanoma skin cancer , significant history cardiac disease , uncontrolled hypertension , unstable medical issue , brain leptomeningeal , prior therapy trastuzumab , uncontrolled seizure disorder , seropositive HIV , active hepatitis , hemorrhagic diathesis require supplemental oxygen .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Uterine serous papillary carcinoma</keyword>
	<keyword>Type II endometrial cancer</keyword>
	<keyword>HER2/neu</keyword>
	<keyword>Paclitaxel , Carboplatin , Trastuzumab</keyword>
</DOC>